Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future

Related Articles

Dell's AI Transformation: How a $51 Billion Backlog Redefines its Future, Despite Margin Headwinds

1 months ago

Is Infosys's Acquisition Strategy Fueling Future Growth

4 months ago

What Does Apple's Executive Exodus Signal for Its Future

5 months ago

What Does Eightco's $125 Million Funding Mean for Its Strategic Pivot

5 months ago

Category

You may also like

Stock News•1 week ago

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience and Redx Pharma agreed to combine, creating Nasdaq-listed Fibrx Therapeutics, a fibrosis-focused company led by Redx management. Concurrent financings of ~$125 million will fund operat...

SKYE

Share

Stock News•1 months ago

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Zymeworks acquired Theravance Biopharma for $929M, gaining Yupelri's ~$60M annual cash flows with patent protection to 2039, diversifying beyond oncology and reducing equity reliance.

ZYME

Share

Stock News•2 months ago

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

ENA Respiratory received USPTO Notice of Allowance for two patents covering TLR2 agonists and rhinovirus-mediated COPD exacerbations, strengthening its IP position for respiratory infection prevention...

Share

Stock News•3 months ago

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences outlined a transition phase during its Q1 2026 earnings call, highlighting new leadership, recent financing, and manufacturing adjustments. These strategic shifts support the com...

ACHV

Share